Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$1.80
-$0.21(-4.99%)
At close: 4:00 PM EST
$1.80
-$0.21(-4.99%)
Day’s Range― - ―
52-Week Range$1.16 - $4.56
Previous CloseN/A
Volume446.20K
Average Volume (3M)1.48M
Market Cap
$82.73M
Enterprise Value$72.78M
Total Cash (Recent Filing)$46.06M
Total Debt (Recent Filing)$646.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Jul 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding68,369,896
10 Day Avg. Volume1,392,178
30 Day Avg. Volume1,476,490
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue138.63
Enterprise Value/Gross Profit-6.58
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$6.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$239.44K
Bulls Say, Bears Say
Bulls Say
Promising Phase 2 Onvansertib DataThe randomized Phase 2 showed a 72% objective response rate versus control and a PFS advantage, and company says this supports a clear registrational path with a selected 30 mg dose. That outcome materially strengthens the long‑term commercial and regulatory trajectory for the lead asset.
Strengthened Executive BenchAdding an experienced CEO, CFO and COO provides durable operational and capital‑markets capability during pivotal development. Seasoned leadership improves trial execution, regulatory interactions and financing strategy, which materially affects the company’s ability to deliver on a Phase 3/registrational plan.
Low Financial LeverageThe company’s minimal debt load materially reduces near‑term default and interest expense risk, giving flexibility to raise capital on development timelines. Low leverage is a durable balance sheet characteristic that supports continuity of R&D spending through financing cycles.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow near $37M TTM means the company must repeatedly access external capital to fund trials. That structural cash burn creates ongoing dilution risk and can constrain timelines and strategy if financing windows tighten.
License / IP Dispute Over Lead AssetActive litigation and a termination notice over the onvansertib license threaten Cardiff’s control of its lead program. Loss or delay of IP rights would materially impair the development, regulatory submission and commercialization path, making this a structural operational and value risk.
Shrinking Equity Base & Dilution RiskSharp erosion of shareholders’ equity over time, combined with shareholder approval to expand the equity incentive reserve, underscores reliance on equity funding. Persistent losses plus planned share issuance raise lasting dilution risk and reduce financial cushion for future financing.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.16 and its highest was $4.55 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $82.73M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on May 14, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.045.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 68,369,896 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went down -3.468%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (233.33% Upside)
$6.00 (233.33% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.93%
12-Months-Change
Fundamentals
Return on Equity
-95.50%
Trailing 12-Months
Asset Growth
-42.02%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias. Additionally, Cardiff Oncology is advancing TROV-054 in Phase 1b/2 trials, exploring its combination with FOLFIRI and bevacizumab, and TROV-053 in a Phase II clinical trial, where it is being assessed alongside Zytiga for metastatic castration-resistant prostate cancer. Established in 1999, the company, which primarily supplies its pharmaceutical innovations to manufacturers, was originally known as Trovagene, Inc. It officially rebranded to Cardiff Oncology, Inc. in May 2012.
CRDF Stock 12 Month Forecast
Average Price Target
$6.00
▲(233.33% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
4.18% Insiders
7.95% Mutual Funds
12.79% Other Institutional Investors
66.91% Public Companies and
Individual Investors